Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Gils

Showing results (41-50 of 162) with videos related to

Pageof 17
Sort By:
Circulation Research|December 8, 2007
Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitorKarlien Buelens, Kerstin Hillmayer, Griet Compernolle, et al.
Therapeutic Drug Monitoring|February 24, 2017
Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory DiseasesAnn Gils, Antonio Bertolotto, Denis Mulleman, et al.
Inflammatory Bowel Diseases|August 18, 2017
Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug WindowKonstantinos Papamichael, Niels Vande Casteele, Marc Ferrante, et al.
Biochemical and Biophysical Research Communications|September 11, 2004
Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibilityBart De Taeye, Ann Gils, Nele Vleugels, et al.
Biochemistry|September 15, 2005
Function-stabilizing mechanism of plasminogen activator inhibitor type 1 induced upon binding to alpha1-acid glycoproteinKatarzyna Smolarczyk, Ann Gils, Joanna Boncela, et al.
Thrombosis and Haemostasis|May 6, 2011
Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanismsNiraj Mishra, Ellen Vercauteren, Jan Develter, et al.
Therapeutic Drug Monitoring|March 23, 2017
Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel DiseaseIris Detrez, Thomas Van Stappen, María D Martín Arranz, et al.
Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology|October 2, 2012
Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applicationsMaarten Bloemen, Ward Brullot, Tai Thien Luong, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 5, 2016
Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against EtanerceptIris Detrez, Els Brouwers, Miet Peeters, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 3, 2007
Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variationClaes Ladenvall, Ann Gils, Katarina Jood, et al.
Pageof 17

Showing results (41-50 of 162) with videos related to

Sort By:
Pageof 17
Circulation Research|December 8, 2007
Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitorKarlien Buelens, Kerstin Hillmayer, Griet Compernolle, et al.
Therapeutic Drug Monitoring|February 24, 2017
Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory DiseasesAnn Gils, Antonio Bertolotto, Denis Mulleman, et al.
Inflammatory Bowel Diseases|August 18, 2017
Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug WindowKonstantinos Papamichael, Niels Vande Casteele, Marc Ferrante, et al.
Biochemical and Biophysical Research Communications|September 11, 2004
Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibilityBart De Taeye, Ann Gils, Nele Vleugels, et al.
Biochemistry|September 15, 2005
Function-stabilizing mechanism of plasminogen activator inhibitor type 1 induced upon binding to alpha1-acid glycoproteinKatarzyna Smolarczyk, Ann Gils, Joanna Boncela, et al.
Thrombosis and Haemostasis|May 6, 2011
Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanismsNiraj Mishra, Ellen Vercauteren, Jan Develter, et al.
Therapeutic Drug Monitoring|March 23, 2017
Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel DiseaseIris Detrez, Thomas Van Stappen, María D Martín Arranz, et al.
Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology|October 2, 2012
Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applicationsMaarten Bloemen, Ward Brullot, Tai Thien Luong, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 5, 2016
Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against EtanerceptIris Detrez, Els Brouwers, Miet Peeters, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 3, 2007
Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variationClaes Ladenvall, Ann Gils, Katarina Jood, et al.
Pageof 17